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Neuritic plaques are a defining feature of Alzheimer disease (AD) pathology. These structures are composed 
of extracellular accumulations of amyloid-β peptide (Aβ) and other plaque-associated proteins, surrounded by 
large, swollen axons and dendrites (dystrophic neurites) and activated glia. Dystrophic neurites are thought to 
disrupt neuronal function, but whether this damage is static, dynamic, or reversible is unknown. To address 
this, we monitored neuritic plaques in the brains of living PDAPP;Thy-1:YFP transgenic mice, a model that 
develops AD-like pathology and also stably expresses yellow fluorescent protein (YFP) in a subset of neurons 
in the brain. Using multiphoton microscopy, we observed and monitored amyloid through cranial windows in 
PDAPP;Thy-1:YFP double-transgenic mice using the in vivo amyloid-imaging fluorophore methoxy-X04, and 
individual YFP-labeled dystrophic neurites by their inherent fluorescence. In vivo studies using this system 
suggest that amyloid-associated dystrophic neurites are relatively stable structures in PDAPP;Thy-1:YFP trans-
genic mice over several days. However, a significant reduction in the number and size of dystrophic neurites 
was seen 3 days after Aβ deposits were cleared by anti-Aβ antibody treatment. This analysis suggests that ongo-
ing axonal and dendritic damage is secondary to Aβ and is, in part, rapidly reversible.
Introduction
Alzheimer disease (AD) is a neurodegenerative disorder that 
results in memory deficits, changes in personality, and cognitive 
decline. It is the leading cause of dementia in the US, affecting 
approximately 10% of those over 65 and 50% of those over 85 years 
of age. One of the invariant pathological hallmarks of AD is the 
presence of neuritic plaques in areas of the brain responsible for 
memory and cognition. Neuritic plaques consist predominantly 
of extracellular fibrils of amyloid-β peptide (Aβ) and are closely 
associated with dystrophic neurites, activated microglia, and reac-
tive astrocytes (1–3). The actual mechanisms that contribute to the 
pathogenesis of AD are not known; however, compelling genetic 
and biochemical evidence suggests that accumulation of amyloid-
β protein plays a central role. Thus, preventing or reversing the 
formation of amyloid may be a viable treatment.
The dystrophic neurites that surround amyloid deposits are 
markedly swollen, distorted axons and dendrites. In AD, the num-
ber of dystrophic neurites has been shown to correlate with the 
clinical severity of dementia (4), and neuronal dystrophy is asso-
ciated with synaptic loss in cortical cultures exposed to fibrillar 
Aβ (5). Studies in human AD and in transgenic models suggest 
that alterations in dendritic curvature and morphology, including 
neuritic dystrophy, that are associated with deposits of fibrillar Aβ 
are likely to profoundly effect neural network function, as ascer-
tained by computer modeling (6, 7). Though neuritic dystrophy 
is thought to contribute to cognitive impairment by disrupting 
neuronal function, many physiological characteristics of dystro-
phic neurites in vivo remain largely unknown.
Various studies have shown that different anti-Aβ immunother-
apies can reduce the amount of brain Aβ deposits in transgenic 
mouse models of AD (8–19). It is not known, however, whether 
removal of Aβ would reverse neuritic dystrophy and, if so, how rap-
idly this would occur. Insight into the stability of amyloid plaques, 
diffuse Aβ deposits, and cerebral amyloid angiopathy (CAA) in AD 
transgenic mouse models has been obtained by in vivo brain imag-
ing using 2-photon microscopy (10, 11, 20–22). When monitored 
over a 5-month period using this technique, dense-cored amyloid 
plaques in the brains of living APP transgenic mice were seen to 
develop very rapidly and for the most part to remain stable in size 
and shape, while a small population of plaques appeared to under-
go periods of dynamic growth and shrinkage (21). It was further 
shown that topical application of antibodies specific for the Aβ 
protein to the brains of APP transgenic mice could promote clear-
ance of diffuse Aβ deposits and amyloid as monitored by 2-pho-
ton microscopy over a 3- to 8-day period (10, 11). Attempts have 
been made to observe neurite changes associated with amyloid in 
vivo using fluorescent dextrans to label neurites in transgenic mice 
(23). These studies showed that dense-cored plaques could alter 
neurite trajectories and disrupt the neuropil in a relatively large 
area surrounding the core, but this type of labeling approach was 
not conducive to high-resolution, long-term analysis of neuronal 
structures in vivo.
Nonstandard abbreviations used: Aβ, amyloid-β peptide; AD, Alzheimer disease; 
CAA, cerebral amyloid angiopathy; YFP, yellow fluorescent protein.
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To study the dynamics of neurite-amyloid interactions and to 
investigate the properties of amyloid toxicity in vivo, we analyzed 
neuritic plaques in the brains of living PDAPP;Thy-1:YFP transgen-
ic mice, a transgenic mouse model that develops AD-like pathol-
ogy and also stably expresses yellow fluorescent protein (YFP) in 
a subset of neurons in the brain (24). In PDAPP;Thy-1:YFP double-
transgenic mice, large YFP-labeled dystrophic axons and dendrites 
associated with fibrillar deposits of Aβ are easily visualized (24). 
In the present study, using multiphoton microscopy, we observed 
and monitored amyloid through cranial windows in PDAPP;Thy-1: 
YFP double-transgenic mice using the in vivo amyloid-imaging 
fluorophore methoxy-X04 (25), and individual YFP-labeled dys-
trophic neurites adjacent to amyloid were visualized over time by 
virtue of their inherent fluorescence. We have used this system to 
investigate whether amyloid-associated dystrophic neurites under-
go dynamic changes over time and whether rapid clearance of Aβ 
has an acute affect on neuritic dystrophy in living PDAPP;Thy-1:
YFP double-transgenic mice.
Results
Using an in vivo imaging system, we monitored amyloid-associ-
ated dystrophic neurites in the brains of living PDAPP;Thy-1:YFP 
double-transgenic mice using multiphoton microscopy. In the 
neocortex, these mice express YFP in layer 5 neuronal cell bodies 
and their dendrites that extend to the cortical surface. Through 
cranial windows, cerebrovascular and parenchymal amyloid 
deposits were observed with systemically injected methoxy-X04, 
and YFP-labeled dystrophic neurites were visualized by their inher-
ent fluorescence (Figure 1). Figure 1, D–F, shows a neuritic plaque 
with multiple large dystrophic neurites imaged in vivo on the ini-
tial day of surgery. The exact location of each neuritic plaque ana-
lyzed was mapped by virtue of crude stereotaxic coordinates and 
more precisely by their relative positions to cerebral blood vessels 
(either affected or unaffected by CAA) and other stable fiduciary 
markers in the vicinity of the plaque (Figure 1, A–C). This map-
ping system enabled us to reproducibly identify the same plaques 
in living PDAPP;Thy-1:YFP double-transgenic mice during imaging 
sessions that were separated by days to weeks (Figure 2).
Using this system, we first analyzed neuritic pathology in living 
double-transgenic mice in the absence of any treatment to deter-
mine whether the number or size of amyloid-associated dystro-
phic neurites changed dynamically over a period of 72 hours. To 
monitor potential changes in populations of dystrophic neurites, 
image stacks that encompassed neuritic plaques were generated 
on the initial day of surgery (day 0), and the same plaques were 
imaged again 3 days later (day 3). The total number and total 
cross-sectional area of dystrophic neurites within a plaque were 
Figure 2
Reimaging of a neuritic plaque in a living PDAPP;Thy-1:YFP double-
transgenic mouse. (A and B) A single neuritic plaque imaged through a 
cranial window in a living PDAPP;Thy-1:YFP double-transgenic mouse 
with 2-photon microscopy on the initial day of surgery. (C and D) The 
same plaque shown in A and B, imaged 3 days after surgery. Multiple 
neurites of normal caliber and dystrophic neurites (arrows) were easily 
visualized with YFP fluorescence (green). A and C show both methoxy-
X04–labeled amyloid (blue) and YFP-labeled neurites. B and D are 
identical to A and C, respectively, but only show the YFP signal. In the 
absence of any treatment, the relative number and size of amyloid-
associated dystrophic neurites did not significantly change over a 72-
hour period. Each panel is a projection of multiple focal planes that 
span approximately 20 μm. Scale bar: 20 μm.
Figure 1
Neuritic plaques and CAA in a living PDAPP;Thy-1:YFP double-
transgenic mouse. Using multiphoton microscopy, we were able to 
observe and monitor amyloid plaques and CAA through cranial win-
dows in PDAPP;Thy-1:YFP double-transgenic mice using the in vivo 
amyloid-imaging fluorophore methoxy-X04 (blue). These images 
were taken approximately 24 hours after an i.p. injection of methoxy-
X04. Amyloid-associated YFP-labeled dystrophic neurites, as well 
as unaffected axons, dendrites, and dendritic spines, were visual-
ized by their inherent fluorescence (green). (A–C) A low-magnifica-
tion view of an area within the cerebral cortex of a PDAPP;Thy-1:
YFP double-transgenic mouse, in which prominent neuritic plaques 
and CAA can be seen. The arrowhead points to CAA and the arrow 
to a neuritic plaque in the brain parenchyma. (D–F) A higher-mag-
nification view of a neuritic plaque found in the same area shown 
in A. (A and D) YFP only; (B and E) methoxy-X04–stained amyloid 
only; (C) merged image of A and B; (F) merged image of D and E. 
Scale bars: A–C, 200 μm; D–F, 20 μm.
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determined for each time point. A dystrophic neurite was defined 
as any enlarged YFP-labeled neurite measuring more than 2.5 μm 
in diameter. The total dystrophic-neurite cross-sectional area for 
a given plaque represents the sum of the largest cross-sectional 
area for each individual dystrophic neurite found within the 
plaque. This last measure is influenced by both number and size 
of individual dystrophic neurites associated with a plaque. Statis-
tical analysis of image data from 23 neuritic plaques in 10 differ-
ent PDAPP;YFP mice indicates that dystrophic neurites did not 
undergo major changes in number or size over a 72-hour period in 
the absence of any treatments (see Figure 5).
We next wanted to determine whether an anti-Aβ antibody that 
reduces the amount of diffuse Aβ and amyloid in the brains of 
PDAPP transgenic mice would promote the rapid recovery of neu-
ritic dystrophy. In previous studies, N-terminal–specific anti-Aβ 
antibodies have been shown to decrease Aβ in a region-specific 
manner in the brains of PDAPP transgenic mice over a 7- to 8-day 
period when administered to the brain surface (10, 11, 16). Using 
one of these anti-Aβ antibodies, 10D5, we also found a reduction in 
the amount of Aβ deposits in the brains of PDAPP;Thy-1:YFP trans-
genic mice in the immediate vicinity of the application of the anti-
body to the cortical surface after 7 days (Figure 3). We sought to 
determine whether application of 10D5 to the cortical surface had 
any effect on the large dystrophic neurites surrounding amyloid 
deposits compared with application of vehicle alone. Interestingly, 
in mice receiving 10D5, there was a rapid morphological recovery 
of some dystrophic neurites that could be observed over as short 
a period as 3 days (Figure 4). While most of the largest dystrophic 
neurites did not appear to change dramatically over this period, 
the smaller dystrophic neurites were often more shrunken, and 
some were no longer observable. In some instances, a neuritic 
swelling that had been present on a normal-appearing dendrite or 
axonal segment disappeared (Figure 4). Statistical analysis of 18 
plaques from 7 different PDAPP;Thy-1:YFP transgenic mice dem-
onstrated that a significant decrease in both number and total 
cross-sectional area of dystrophic neurites occurred after 10D5 
treatment (Figure 5). Several PDAPP;Thy-1:YFP transgenic mice 
receiving 10D5 treatment were followed out to 1 week; the diminu-
tion in neuritic dystrophy persisted, and in some cases the number 
of dystrophic neurites appeared to decrease relative to the 3-day 
time point (data not shown). Based on these data, it appears that 
axonal and dendritic structural damage associated with amyloid 
deposits is not permanent and is, at least in part, reversible over a 
relatively short time frame. Further, the specificity of the antibody 
shows that Aβ itself causes these reversible structural changes.
Because of the rapid change in dystrophic neurites induced by 
10D5, we wanted to know whether application of this antibody 
resulted in a change in total Aβ immunostaining as well as fibril-
lar Aβ. Since it was difficult to quantitate fibrillar deposits in vivo 
using methoxy-X04 in PDAPP;Thy-1:YFP mice, we administered 
10D5 to an additional 4 17- to 18-month-old PDAPP mice and 
assessed Aβ and thioflavine-S–positive staining in the cortex ipsi- 
and contralateral to antibody application. There was a significant 
decrease in both Aβ-positive and thioflavine-S–positive load in 
the cortex ipsilateral to 10D5 application (mean ± SEM; Aβ load: 
treated/untreated cortex = 0.51 ± 0.13, P = 0.03; thioflavine-S load: 
treated/untreated cortex = 0.62 ± 0.107, P = 0.04).
Discussion
The amyloid hypothesis of AD proposes that the onset and pro-
gression of AD pathogenesis is primarily influenced by the accu-
mulation of Aβ in the brain (26). Attention has been given recently 
to the possibility of using Aβ-related immunotherapy to affect this 
accumulation (27). To test whether an anti-Aβ antibody could 
actually influence structural neuronal damage associated with 
neuritic pathology, we monitored amyloid-associated dystrophic 
neurites in living PDAPP;Thy-1:YFP double-transgenic mice treated 
Figure 4
Morphological recovery of amyloid-associated neuritic dystrophy in 
a PDAPP;Thy1:YFP double-transgenic mouse after anti-Aβ antibody 
(10D5) treatment. The 2 panels show the same population of YFP-
labeled neurites, which are associated with a neuritic plaque imaged 
on the initial day of surgery (A) and 72 hours later (B). The antibody 
was administered directly to the surface of the brain during the cranial-
window surgical procedure on day 0. The arrows in the day 0 image (A) 
point to 2 enlarged dystrophic neurites, which are absent in the day 3 
image (B). The associated amyloid is not shown. Scale bar: 20 μm.
Figure 3
Clearance of Aβ deposits by direct application of anti-Aβ antibody to 
the surface of the brain. (A) Aβ immunoreactivity in a coronal sec-
tion from the brain of a PDAPP;YFP double-transgenic mouse that 
received no treatment. The mouse was fitted with a cranial window on 
day 0 and sacrificed 7 days later. (B) Aβ immunoreactivity in a coronal 
section from the brain of a PDAPP;YFP double-transgenic mouse that 
received treatment with an N-terminal–specific anti-Aβ antibody (20 
μg of 10D5). The antibody was administered directly to the surface 
of the brain, directly under the cranial window, during the surgical 
procedure on day 0 and sacrificed 7 days later. In both A and B, the 
area of the brain exposed by the cranial window lies between the 
arrowheads. (C) A higher magnification of the cortical area exposed 
by the cranial window in the untreated brain shown in A. (D) A higher 
magnification of the cortical area exposed by the cranial window in 
the 10D5-treated brain shown in B. Note the region of reduced Aβ 
immunoreactivity within 100–200 μm below the cortical surface in the 
treated area. Scale bars: 250 μm.
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with the anti-Aβ mAb 10D5. In previous studies, 10D5 treatments 
were shown to cause a local, rapid decrease in the amount of Aβ 
deposits in the brains of APP transgenic mice when administered 
to the brain surface (10, 11, 16). Using the combination of YFP 
to label neurites and methoxy-X04 (25) to label amyloid, we were 
able to efficiently monitor morphologically normal and dystro-
phic amyloid-associated neurites over time with high resolution 
using 2-photon microscopy in vivo.
In this study, we found that the amount of plaque-associated 
neuritic dystrophy did not change significantly over a 3-day period 
in control animals. This is consistent with observations made in 
live brain slices taken from PDAPP;Thy-1:YFP double-transgenic 
mice in which dystrophic neurites associated with neuritic plaques 
did not exhibit dramatic morphological changes when imaged 
over short time periods with fluorescence confocal microscopy 
(28). The apparent stability of neuritic dystrophy, in both mod-
els, probably reflects the chronic nature of this type of injury that 
develops over a period of days to months. Conversely, when ani-
mals received the anti-Aβ antibody treatment, a rapid reversal of 
amyloid-associated neuritic dystrophy was seen. This result was 
striking in that it demonstrates that altering brain Aβ can facili-
tate an acute response to chronically injured axons and dendrites. 
It also suggests that the confirmed presence of uncleared Aβ in the 
brain contributes to ongoing structural damage to neurites and is 
required for at least some of this damage to persist.
The exact mechanism of the effect elicited by direct application 
of 10D5 antibody to the brain surface is unclear, although several 
possibilities exist. Recent studies have demonstrated that anti-Aβ 
antibody–induced clearance of deposited Aβ appears to facilitate 
the correction of abnormal plaque-associated neurite curvatures 
in PDAPP transgenic mice (16) and promotes the clearance of 
early tau pathology in the hippocampal regions of 3xTg-AD mice 
(17), a transgenic model that develops both amyloid plaques and 
neurofibrillary tangles (29). Oddo et al. (29) showed that anti-Aβ 
antibody injections into the hippocampus resulted in decreased 
tau staining in the somatodendritic compartment of neurons by 
5 days. While their study demonstrated that Aβ clearance could 
modify the accumulation of cytoplasmic protein staining for tau, 
it did not address whether the anti-Aβ antibodies could elicit a 
change in the enlarged, distorted axons and dendrites that sur-
round amyloid plaques (i.e., the structural change we know as neu-
ritic dystrophy). Our study and that of Oddo et al. complement 
each other in that both show that Aβ clearance may enable the 
recovery of a specific abnormality associated with Aβ deposition. 
The pathological changes that we were able to assess as well as the 
methods that we used allowed us to evaluate an important aspect 
of AD-like pathology that was not amenable to prior investiga-
tions. By using multiphoton microscopy and intrinsically labeled 
neuronal processes, we were able to detect decreases in the size of 
enlarged axonal and dendritic swellings in individual plaques over 
time. This effect may be due to clearance and/or neutralization 
of deposited Aβ. A recent study using electrophysiological mea-
surements in vivo has shown that the insoluble Aβ aggregates are 
associated with a disruption in neocortical synaptic function that 
is not seen when only soluble forms are present (30). This supports 
not only the idea that rapid improvement in neurite structure can 
come from clearing of insoluble Aβ deposits but also the idea that 
rapid shrinkage of dystrophic neurites has the potential to rap-
idly improve neuronal and synaptic function. It is conceivable that 
some of the rapid behavioral improvements seen following passive 
peripheral administration of anti-Aβ antibodies could occur via 
rapid changes in dystrophic neurites (31, 32). It will be important 
in future studies to directly assess axonal, dendritic, and synap-
tic function in conjunction with the improvement in structural 
abnormalities induced by anti-Aβ antibodies. 
In the time frame in which our analysis was performed, the 
amyloid cores of the neuritic plaques as assessed by 2-photon 
microscopy were still present, but it was not possible, with this 
technique, to quantify whether there was an antibody-induced 
decrease in amyloid. To address this, we treated a separate group 
of PDAPP mice with 10D5 and found that there was a significant 
decrease in both Aβ-immunostained and thioflavine-S–positive 
plaques. In a separate group of PDAPP mice, we also assessed 
whether application of 10D5 to the cortex affected levels of PBS-
soluble Aβ over 3 days. We found that this treatment resulted in no 
significant change in PBS-soluble Aβ40 or Aβ42 in the treated ver-
sus the untreated cortex (data not shown). Taken together, these 
results suggest that antibody-induced decrease in the number and 
size of dystrophic neurites is due to an effect on fibrillar Aβ.
The observation that only a limited number of dystrophic areas 
seemed to recover may reflect the initial phases of an acute response 
to a single antibody treatment that might be enhanced with addi-
tional time or antibody doses. Alternatively, it may reflect differ-
ences in the state of the neuritic injury. For example, dystrophic 
neurites that are larger and more mature may not respond to Aβ 
clearance as well as a newly developed dystrophic neurite. Thus, 
more of a benefit might be seen in younger animals that are just 
beginning to develop pathology. To our knowledge, this study pro-
vides the first direct evidence that reducing Aβ in the brain can pro-
mote the rapid structural recovery of existing amyloid-associated 
neuritic dystrophy in vivo. These data have important implications 
regarding Aβ clearance as a therapeutic strategy for AD. Our in vivo 
imaging model should prove to be a valuable tool to study the nor-
Figure 5
Repeated-measures ANOVA on data derived from 23 neuritic plaques 
imaged from 10 different untreated PDAPP;YFP transgenic mice and 
18 plaques imaged from 7 different 10D5-treated PDAPP;Thy-1:YFP 
transgenic mice. All dystrophic neurites were imaged on day 0 and 
then reimaged on day 3. A significant treatment × day interaction for 
both the mean number [F1,28 = 25.092, P = 0.00003] of dystrophic 
neurites (A) and the mean total cross-sectional area [F1,28 = 21.037, 
P = 0.00009] of dystrophic neurites (B) was seen. In the absence of 
treatment, dystrophic neurites did not undergo significant changes 
in regard to number or cross-sectional area over a 72-hour period. 
However, a significant decrease in both mean number and mean 
cross-sectional area was seen in animals receiving 10D5 treatment. 
*P < 0.00005 versus untreated group.
Downloaded on June  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/23269
research article
432 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 2   February 2005
mal progression of AD-like pathology in transgenic mice and to 
assess a wide range of clinically relevant treatments for AD.
Methods
Animals. PDAPP+/–;Thy-1:YFP+/– double-transgenic mice were generated 
as described previously (24, 33, 34). All double-transgenic mice used for 
this analysis were 17–18 months of age. All animal procedures used in this 
study have been approved by the Institutional Review Board at Washington 
University School of Medicine.
Surgical procedures. The cranial-window surgical procedure was performed 
as described elsewhere with slight modifications (23, 35). Briefly, animals 
were anesthetized with isoflurane (4% induction, 1.5% maintenance) 
while being immobilized in a custom-made animal stereotaxic apparatus 
equipped with an anesthetic mask. The skin was resected from just posteri-
or to the eyes to the base of the skull, and a hole, approximately 4–6 mm in 
diameter, was carved into the skull between bregma and lambda with a fine 
drill bit. After drilling, the resulting “bone cap” was carefully removed, and 
the dura was removed from the exposed brain region. The exposed brain 
region was irrigated, and an 8-mm cover glass was sealed to the skull with 
dental cement to cover the hole. Animals receiving antibody treatment had 
an anti-Aβ mAb, 10D5 (10 μl of a 2-mg/ml solution in Ca++- and Mg++-free 
PBS), applied to the exposed brain surface before placement and sealing of 
the cover glass (16, 23). Untreated animals used as controls underwent the 
same procedure as antibody-treated animals except that PBS without 10D5 
antibody was applied to the brain surface.
In vivo brain imaging using 2-photon microscopy. Twenty-four hours before 
imaging, PDAPP;Thy-1:YFP transgenic mice were injected i.p. with 10 mg/kg 
methoxy-X04 to specifically label amyloid in the brain (25). Anesthetized 
mice with cranial windows were placed on the stage of a 2-photon micro-
scope (LSM 510 META NLO system [Carl Zeiss Inc.] with a Chameleon Ti:
Sapphire laser [Coherent Inc.]) while in our custom stereotaxic device. For 
simultaneous imaging of methoxy-X04 and YFP, an excitation wavelength 
of 860 nm was used. Fluorescence emission from amyloid-bound methoxy-
X04 and YFP was collected in the ranges of 435–485 nm and 525–650 nm, 
respectively. Higher-resolution imaging of YFP-labeled neurites alone was 
done with an excitation wavelength of 920 nm. Low-magnification images 
were taken to establish map positions of neuritic plaques relative to the 
vasculature and other fiduciary markers within the brain. Individual neu-
ritic plaques were imaged with an Achroplan ×40 infrared water immer-
sion lens (0.8 numerical aperture; Carl Zeiss Inc.) for analysis. Images were 
acquired as 512 × 512 arrays of 8-bit pixels in z-series stacks originating 
at the cortical surface and proceeding downward with a step size approxi-
mately equal to the excitation wavelength being used. Z-stack data were 
collected for each plaque analyzed on the day of the cranial-window sur-
gery (day 0) and 72 hours after surgery (day 3).
Data analysis. Image stacks from each imaging session were processed 
and analyzed using both AIM (version 3.2; Carl Zeiss Inc.) and Metamorph 
(version 6.1; Universal Imaging Corp.) software. Three-dimensional recon-
struction of neuritic plaques from z-series stacks was made using maxi-
mum-intensity projections. The resulting 3D images obtained at different 
time points for an individual plaque were rotated in space to obtain the 
same orientation for analysis. The total number and total cross-section-
al area of dystrophic neurites within a plaque were determined for each 
time point. A dystrophic neurite was defined as any enlarged YFP-labeled 
neurite measuring more than 2.5 μm in diameter. The total dystrophic-
neurite cross-sectional area for a given plaque represents the sum of the 
largest cross-sectional area for each individual dystrophic neurite found 
within the plaque. The number and size of dystrophic neurites associated 
with each plaque were compared for the 2 time points.
Statistical analysis. The data were analyzed using STATISTICA 6.0 for Win-
dows (StatSoft Inc.), and levels of P < 0.05 were set for significance. Data 
regarding the mean number and mean total cross-sectional area of dystro-
phic neurites were analyzed with repeated-measures ANOVAs that includ-
ed 1 within-subjects factor (day 0 vs. day 3) and 1 between-subjects factor 
(treatment yes vs. no). P values for comparisons exceeding Bonferroni cor-
rected levels (0.05/2 = 0.025) are signified in Figure 5 by asterisks.
Histological analysis. When in vivo analysis was completed on an animal, it 
received a 200-mg/kg i.p. injection of pentobarbital followed by a bilateral 
thoracotomy and perfusion of 4% paraformaldehyde in PBS through the left 
ventricle. Brains were dissected and postfixed in the same fixative overnight at 
4°C, and then incubated in 30% sucrose in PBS overnight. Brains were cut into 
50-μm sections using a freezing sliding microtome. Immunohistochemical 
localization of Aβ- and thioflavine-positive plaques was performed on sec-
tions containing treated and nontreated areas to determine the relative densi-
ties of Aβ deposits and amyloid as described previously (24).
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